In view of these new developments on leukemia-associated reciprocal fusion genes and on the requirement for cooperating genetic events in PAX3-FKHR-driven ARMS, it seems premature to dismiss a biological contribution of FKHR-PAX3 in ARMS solely based on its expression pattern in well-established tumor samples. This evidence concerns the gene PAX3 and leukemia.